Colorectal Cancer Screening definition

Colorectal Cancer Screening means a colorectal cancer examination and laboratory test recommended by a Physician in accordance with the most recently published colorectal cancer screening guidelines of the National Cancer Society.
Sample 1Sample 2Sample 3
Colorectal Cancer Screening means any of the following
Sample 1Sample 2Sample 3
Colorectal Cancer Screening means a colorectal cancer examination and laboratory test recommended by a Provider in accordance with the most recently published colorectal cancer screening guidelines of a national cancer society. If a colonoscopy is recommended as the colorectal cancer screening method and a lesion is discovered and removed during the colonoscopy, Benefits will be paid for the screening colonoscopy as the primary procedure. See section
Sample 1Sample 2Sample 3

Examples of Colorectal Cancer Screening in a sentence

  • NCQA/ HEDIS X X Colorectal Cancer Screening Percent of plan members aged 50-75 who had appropriate screening for colon cancer.

  • The Manitoba Colorectal Cancer Screening Program has now changed its name to ColonCheck Manitoba.

  • Routine Digital Rectal ExamI Member cost sharing is based on the Member cost sharing is based on the specific Test type of service and the type of service and the place of service where it is rendered place of service where it is rendered Colorectal Cancer Screening Member cost sharing is based on the Member cost sharing is based on the For all members age 50 and over.

  • Enrolled employees in the medical plan must complete: • At least one (1) of the following routine/preventative services (When age and gender appropriate) o Bone Density o Breast Cancer Screening o Complete Blood Count o Cervical Cancer Screening o Cholesterol Screening o Colorectal Cancer Screening o Diabetes Screening o Glucose Screening o Lab & Radioimmunoassay o Metabolic Panel o Physical Exam o Prostate Cancer Screening o Urinalysis Data will be retrieved from Medical Mutual’s Claims system.

  • Integrating Colorectal Cancer Screening Within Chronic Disease Programs grant began March 3, 2009.

  • NCQA/ HEDIS X Colorectal Cancer Screening Percent of plan members aged 50-75 who had appropriate screening for colon cancer.

  • Routine Digital Rectal Exam / Prostate-specific Antigen Test Covered 100%; deductible waived Not Covered Colorectal Cancer Screening For all members age 50 and over.

  • Colorectal Cancer Screening Occult blood test, sigmoidoscopy or colonoscopy for colorectal cancer screening for men and women, in accordance with Law No. 218 of August 30, 2012.

  • The Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity number DP15-1502, entitled Organized Approaches to Increase Colorectal Cancer Screening, and application dated February 28, 2017, as may be amended, which are hereby made a part of this Non-Research award hereinafter referred to as the Notice of Award (NoA).

  • Purpose: Provide Technical Planning Support and Subject Matter Expertise for Organized Approaches to Colorectal Cancer Screening Task 1: Xxxxxx Foundation Hospitals will provide consultation, assessment, and expert subject matter technical assistance to support implementation of the Colorectal Cancer Control (CRC) Program (DP15-1502: Organized Approaches to Colorectal Cancer Screening).


More Definitions of Colorectal Cancer Screening

Colorectal Cancer Screening means any of the following procedures that are furnished to an individual for the purpose of early detection of colorectal cancer:
Sample 1Sample 2Sample 3
Colorectal Cancer Screening means all colorectal cancer examinations and laboratory tests recommended by a health care provider in accordance with the most recently published colorectal cancer screening guidelines of a national cancer society.
Sample 1Sample 2

Related to Colorectal Cancer Screening

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Healing arts screening means the testing of human beings using x-ray machines for the detection or evaluation of health indications when such tests are not specifically and individually ordered by a licensed practitioner of the healing arts legally authorized to prescribe such x-ray tests for the purpose of diagnosis or treatment.

  • COVID-19 symptoms means fever of 100.4 degrees Fahrenheit or higher, chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea, unless a licensed health care professional determines the person’s symptoms were caused by a known condition other than COVID-19.

  • Screening Test means a drug or alcohol test which uses a method of analysis allowed by the Minnesota Drug and Alcohol Testing in the Workplace Act to be used for such purposes.

  • Disinfection profile means a summary of Giardia lamblia inactivation through the treatment plant.

  • Prosthesis means an artificial substitute for a missing body part.

  • Health screening means the use of one or more diagnostic tools to test a person for the presence or precursors of a particular disease.

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • sickle cell disease means a hemolytic disorder characterized by chronic anemia, painful events, and various complications due to associated tissue and organ damage; "hemolytic" refers to the destruction of the cell membrane of red blood cells resulting in the release of hemoglobin.

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Cannabinoid edible means food or potable liquid into which a cannabinoid concentrate, cannabinoid extract or dried marijuana leaves or flowers have been incorporated.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Fluoroscopic imaging assembly means a subsystem in which X-ray photons produce a visual image. It includes the image receptor(s) such as the image intensifier and spot-film device, electrical interlocks, if any, and structural material providing linkage between the image receptor and diagnostic source assembly.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Assay means a laboratory analysis of Crude Petroleum to include the following: A.P.I. Gravity, Reid vapor pressure, composition, pour point, water and sediment content, sulfur content, viscosity, distillation, hydrogen sulfide, flash/boiling point and other characteristics as may be required by Carrier.

  • Medical cannabis means the same as that term is defined in Section 26-61a-102.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • COVID-19 test means a viral test for SARS-CoV-2 that is:

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.